Several patient demographic factors, including marital status, have been demonstrated to have prognostic significance for survival in extremity soft tissue sarcoma (ESTS). A study population of 12,546 adult patients diagnosed with ESTS from 1991 to 2010 was identified from the SEER database, a large population-based registry, in order to determine whether overall survival had changed over this recent 20-year period. The study population was divided into three groups by year of diagnosis: 1991–1996, 1997–2003, and 2004–2010. We used the Kaplan-Meier method and Cox proportional hazards regression to assess survival differences between different demographic groups and prognostic clinical characteristics. Over the course of time, the 5-year overall survival rates have increased from 28% in the earliest time period to 62% in the latest ($P < 0.0001$). On multivariate analysis, the mortality rate progressively declined from the 1991–1996 group (HR: 3.02, CI: 2.78–3.29) to the 1997–2003 group (HR: 2.21, CI: 2.06–2.37), with the 2004–2010 group having the best overall survival, despite increases in the proportion of patients with tumors greater than 5 cm in size ($P < 0.0001$), and those presenting with metastasis ($P < 0.0001$).

1. Introduction

Extremity soft tissue sarcomas (ESTS) comprise a collection of rare mesenchymal malignancies [1]. These represent a histologically heterogeneous group of diseases arising from connective tissues, many of which present a high risk of distant metastasis [2–4]. Surgical resection is the mainstay of current treatment approaches, with limb salvage considered a clinically appropriate objective for most tumors [5]. Adjuvant or neoadjuvant radiation has been recognized to reduce the rate of local recurrence, particularly in high-grade tumors. However, there remains a question as to whether radiation therapy may increase overall survival in patients with high-grade soft tissue sarcomas [6–10].

Due to the low incidence of ESTS, most prior studies of this disease have been small and from a single institution [11–15]. Contemporary population-based studies of ESTS have demonstrated clinical and demographic patient factors that may be associated with prognosis [16,17].

The National Cancer Institute's Surveillance, Epidemiology, and End Results (SEER) database provides a mechanism by which to analyze this disease through a cross section of the United States' population [18]. The goal of this study was to assess incidence and survival of ESTS during a 20-year period, from 1991 to 2010, to determine if there have been changes in the overall survival from this disease.

2. Methods

The SEER program is developed by the National Cancer Institute (NCI) for evaluation of population-based cancer statistics in the United States. The database comprises 18 geographic registries, covering approximately 28% of the United States population [19]. Together, these registries encompass the demographic diversity of the US population, with comparable socioeconomic and racial representation.
relative to the national population [20]. Every case of cancer within the registries’ geographic domains is recorded [21].

This database was used to identify a cohort of 15,382 adult patients, age 17 and older, diagnosed with ESTS from 1991 to 2010. Inclusion criteria were diagnosis of sarcoma, primary to connective, subcutaneous, and other soft tissues of the lower limb and hip, or upper limb and shoulder. Patients diagnosed in 2004 or later who had an unknown AJCC Stage, histologic grade, CS tumor size, lymph node involvement, extension, and metastasis at the time of diagnosis were excluded, as were patients diagnosed prior to 2004 whose data were incomplete regarding histologic grade, EOD tumor size, lymph node, and extent. These exclusions yielded a study population of 12,546 patients.

The study population was evaluated based upon demographic characteristics, including age, race, Hispanic ethnicity, sex, marital status, year of diagnosis, and geographic location. Prognostic tumor characteristics that were examined include tumor size, anatomic site (upper versus lower extremity), metastatic disease at presentation, tumor grade, and type of sarcoma. AJCC Stage was only included in the SEER database after 2004. The use of radiation therapy and surgery were included in the analysis as well.

Patients were grouped by year of diagnosis for comparison: 1991–1996, 1997–2003, and 2004–2010. For demographic analysis, race was categorized as White, Black, or Asian/other. Marital status was categorized as single (never married), married (including common law), other (including separated, divorced or widowed), or unknown. The rural-urban continuum code was collapsed into a binary variable: Metro county or Non-Metro county, using guidelines by SEER and ERS [22, 23]. The SEER registries were aggregated into geographic regions: Northeast, South, Southwest, Midwest, and West.

Extracted data was used to categorize tumor size into ≤5 cm, >5 cm, or unknown, and categorize lymph node involvement, extension of the tumor, and presence of metastasis at the time of diagnosis. ICD-O-3 histologic types were collapsed into the following categories: fibromatous connective tissue neoplasm, myxomatous connective tissue neoplasm, lipomatous, myomatous, synovial connective tissue neoplasm, ESTS not otherwise specified (NOS), and all other types, including osteosarcoma, chondrosarcoma, vascular tumors, and Ewing sarcoma.

Incidence rates were analyzed using SEER*Stat (version 8.1.5; NCI, Bethesda, MD). Incidence rates were age-adjusted to the 2000 US Standard Population. Annual percent change was calculated using the weighted least squares method, with the Tiwari modification used for confidence intervals.

Statistical analysis was performed using SAS version 9.3 (SAS Institute, Cary, NC). Survival time was measured in years. Chi-square tests were performed to assess differences between time periods on demographic and clinical factors. Comparisons of survival time among categorical grouping variables were accomplished by the computation of Kaplan-Meier product-limit curves, with the effects of categorical demographic, clinical, pathologic, and treatment variables assessed using the log-rank test. The Bonferroni test was used when performing multiple comparisons. Cox proportional hazards regression was used to estimate survival differences for continuous variables.

Factors that appeared to be significantly associated with survival in univariate analysis were considered for inclusion in the Cox proportional hazards regression multivariable model. A result was considered statistically significant with a P value < 0.05. Efron’s method was used to adjust for tied failure times.

### 3. Results

A majority of patients in this study were 60 years of age or older (50%), Caucasian (82%), and married (60%). The population was 54% male and 46% female. The most common histologic diagnoses were fibromatous (33%) and lipomatous (24%). The least common was myxomatous (0.81%). Tumors occurred more frequently in the lower limb (74%) than the upper limb (26%).

The 5-year overall survival of ESTS improved progressively during the study period, from 28% in 1991–1996, to 40% in 1997–2003, to 62% in 2004–2010 (Figure 1). There was a significant difference between these survival curves (P < 0.0001). The incidence of ESTS increased slightly during the study period, from 1.5/100,000 in 1991, to 2.0/100,000 in 2010. This represents an annual percent change of 1.2% (Figure 2).

The clinical picture of the adult ESTS population also changed significantly during the 20-year study period (Table 1). The population became older, with the proportion of patients 60-years of age and older increasing modestly between time periods, from 49.7% to 52.0% (P < 0.0001). Similarly, the proportion of patients under the age of 30 decreased from 9.2% to 6.8% (P < 0.0001).

Among patients with known disease grade, the patient population in 2004–2010 presented with more advanced disease than did patients in 1991–1996, with the proportion
of patients presenting with high-grade tumors increasing from 51.8% to 61.2%. Among patients whose metastatic status at presentation was known, there was an increase in the percentage of patients who presented with metastasis over the course of the study, from 9.5% in the earliest time period to 14.9% in the most recent. Similarly, the proportion of patients with tumors >5 cm increased from 60.4% to 66.7% over the study period. These aforementioned differences between time periods demonstrated statistical significance (Table 1). Anatomical tumor location changed significantly throughout this study period as well, with the proportion of lower limb tumors increasing from 71.7% to 75.4% (P = 0.0034).

The effects of race, ethnicity, and county metropolitan status were not consistent throughout this study period. When comparing the univariate results (Table 2), Hispanic ethnicity was a significant factor only during the 1997–2003 time period, during which time Hispanic patients had improved overall survival over non-Hispanic patients (P = 0.0004). Race was not a significant factor during the 1991–1996 time period. However, African Americans had a decreased overall survival when compared to Caucasians in 2004–2010 (P = 0.0332). County metropolitan status was significant only during the 1997–2003 time period, during which patients in metro counties had increased overall survival compared to patients in non-Metro counties (P < 0.001).

While the percentage of patients treated with surgery remained constant, the use of radiation therapy increased during this study period, with the proportion of patients receiving radiation therapy increasing from 48.8% to 53.0% (P < 0.0001). This slight change in the use of neoadjuvant or adjuvant radiation temporally relates to the publication of two major randomized control trials during the initial study period.

On multivariate analysis, the mortality rate progressively declined from the 1991–1996 group (HR: 3.02, CI: 2.78–3.29), to the 1997–2003 group (HR: 2.21, CI: 2.06–2.37), with the 2004–2010 reference group, having the best overall survival, while adjusting for age, Hispanic ethnic status, registry region, marital status, county foreign born percent, percent with high school graduation, treatment with radiation and surgery, histologic type, metastatic disease status, tumor size, grade, and anatomic site (Table 3). Results from the multivariate analysis showed each of these factors to be independent predictors of survival, excluding anatomic site and registry region; though site and region were not statistically significant, these factors were kept in the final model due to clinical importance and improvement of model fit. Lastly, interaction between tumor size and anatomic site was also assessed, but the results were not statistically significant and are therefore not reported.

**4. Discussion**

Overall survival of ESTS improved over time in our 20-year study. This improvement in overall survival occurred despite increases in the proportion of older patients, as well as increases in the proportions of patients with large tumors and those with metastatic disease. ESTS is understood to have a bimodal age distribution [24]. It is therefore not surprising that as the US population ages, the proportion of older patients diagnosed with ESTS will increase. In fact, the current findings suggest that the overall incidence of ESTS may be increasing slightly over time. It is, however, surprising that despite increases in the proportion of patients with tumors >5 cm size, as well as those with metastatic disease at the time of diagnosis, overall survival improved with time. This is in contrast to the dogma that earlier detection of smaller tumors leads to increased survival in other cancers [25–28]. While this study cannot determine whether earlier detection may have influenced prognosis, these results indicate that the more recent study populations presented at an apparently later stage in the disease course. These findings may potentially be attributable to improvements in the ability for advanced imaging to detect distant metastases, though such an analysis is beyond the scope and limitations of the current analysis.

The use of radiation increased over the course of this study period, from 49% in 1991–1996 to 53% in 2004–2010. Most prior studies have failed to demonstrate an improvement in overall survival with radiation therapy [8, 29, 30]. Our results, however, demonstrate radiation therapy to be an independent prognostic indicator of overall survival. A previous analysis of the SEER database also demonstrated an association between radiation therapy and improved overall survival in patients with high-grade ESTS [6]. Given that the previous study likely included an overlapping study population to that in the current analysis, our findings may represent a confirmation of the prior analysis. Interestingly, in the current study, when the use of radiation was included in multivariate analysis, the year of diagnosis remained a significant predictor of overall survival. This suggests that the improvement in survival is unlikely to be entirely explained by increased use of adjuvant or neoadjuvant radiation therapy.

Due to limitations in the available data within the SEER program, it is difficult to accurately assess local recurrence rates after surgery or radiation therapy. Randomized controlled trials have suggested that radiation may decrease the rates of local recurrence following surgery in ESTS, particularly in high-grade tumors [8, 30]. Several studies have attempted to correlate the relative benefit of radiation therapy...
Table 1: Descriptive statistics of the study population (n = 12,546).

| Characteristic          | 1991–1996 (n = 2122) | 1997–2003 (n = 5221) | 2004–2010 (n = 5203) | P value<sup>a</sup> |
|-------------------------|----------------------|----------------------|----------------------|--------------------|
| **Sex**                 |                      |                      |                      |                    |
| Male                    | 52.6                 | 53.7                 | 54.9                 | 0.1802             |
| Female                  | 47.4                 | 46.3                 | 45.1                 |                    |
| **Site**                |                      |                      |                      | 0.0034<sup>*</sup> |
| Lower limb              | 71.7                 | 73.5                 | 75.4                 |                    |
| Upper limb              | 28.3                 | 26.5                 | 24.6                 |                    |
| **Hispanic**            |                      |                      |                      | <0.0001<sup>*</sup>|
| Non-Hispanic            | 90.7                 | 88.8                 | 87.1                 |                    |
| Spanish-Hispanic-Latino | 9.3                  | 11.2                 | 13.0                 |                    |
| **Radiation**           |                      |                      |                      | <0.0001<sup>*</sup>|
| No                      | 49.7                 | 48.6                 | 45.2                 |                    |
| Yes                     | 48.8                 | 48.8                 | 53.0                 |                    |
| Unknown                 | 1.5                  | 2.6                  | 1.9                  |                    |
| **Surgery**             |                      |                      |                      | 0.31               |
| No                      | 8.4                  | 7.6                  | 8.3                  |                    |
| Yes                     | 91.0                 | 91.7                 | 91.2                 |                    |
| Unknown                 | 0.6                  | 0.7                  | 0.5                  |                    |
| **Marital status**      |                      |                      |                      | 0.141              |
| Single                  | 16.7                 | 18.5                 | 17.9                 |                    |
| Married                 | 58.2                 | 57.5                 | 58.0                 |                    |
| Other                   | 21.25                | 19.8                 | 20.8                 |                    |
| Unknown                 | 3.6                  | 4.2                  | 3.4                  |                    |
| **Age**                 |                      |                      |                      | <0.0001<sup>*</sup>|
| <30                     | 9.2                  | 8.0                  | 6.8                  |                    |
| 30–59                   | 41.1                 | 44.4                 | 41.2                 |                    |
| 60+                     | 49.7                 | 47.6                 | 52.0                 |                    |
| **Histology**           |                      |                      |                      | <0.0001<sup>*</sup>|
| NOS                     | 10.7                 | 12.3                 | 22.3                 |                    |
| Fibromatous             | 42.0                 | 37.0                 | 26.4                 |                    |
| Myxomatous              | 0.4                  | 0.6                  | 1.3                  |                    |
| Lipomatous              | 23.9                 | 22.9                 | 26.4                 |                    |
| Myomatous               | 11.0                 | 13.9                 | 13.4                 |                    |
| Synovial                | 7.5                  | 8.3                  | 6.4                  |                    |
| All other types         | 4.6                  | 5.1                  | 4.3                  |                    |
| **Grade**               |                      |                      |                      | <0.0001<sup>*</sup>|
| I                       | 14.4                 | 14.2                 | 18.9                 |                    |
| II                      | 17.2                 | 16.6                 | 18.2                 |                    |
| III                     | 14.9                 | 18.5                 | 22.7                 |                    |
| IV                      | 19.0                 | 25.2                 | 35.8                 |                    |
| Unknown                 | 34.5                 | 25.5                 | 4.5                  |                    |
| **Metastasis**          |                      |                      |                      | <0.0001<sup>*</sup>|
| No                      | 86.1                 | 86.9                 | 85.1                 |                    |
| Yes                     | 9.1                  | 9.4                  | 14.9                 |                    |
| Unknown                 | 4.9                  | 3.7                  | 0                    |                    |
| **Tumor size**          |                      |                      |                      | <0.0001<sup>*</sup>|
| <=5 cm                  | 30.6                 | 30.2                 | 32.4                 |                    |
| >5 cm                   | 46.8                 | 49.5                 | 64.9                 |                    |
| Unknown                 | 22.6                 | 20.3                 | 2.7                  |                    |

<sup>a</sup> Significant on a P < 0.05 level.

NOS: not otherwise specified.

<sup>b</sup> P value for testing of significance between time periods.
| Characteristic | 1991–1996 (n = 2122) | 1997–2003 (n = 5221) | 2004–2010 (n = 5203) | P value | P value | P value |
|---------------|----------------------|----------------------|----------------------|---------|---------|---------|
| Overall       | 0.28                 | 0.40                 | 0.62                 | 0.0183* | 0.0085* | 0.0016* |
| Sex           | 0.30                 | 0.42                 | 0.65                 |         |         |         |
| Male          | 0.25                 | 0.38                 | 0.60                 |         |         |         |
| Female        | 0.30                 | 0.42                 | 0.65                 |         |         |         |
| Site          | 0.0184*              | 0.0020*              | 0.0013*              |         |         |         |
| Lower limb    | 0.27                 | 0.39                 | 0.60                 |         |         |         |
| Upper limb    | 0.30                 | 0.43                 | 0.66                 |         |         |         |
| Hispanic      | 0.4466               | 0.0004*              | 0.0658               |         |         |         |
| Non-Hispanic  | 0.28                 | 0.39                 | 0.61                 |         |         |         |
| Spanish-Hispanic-Latino | 0.22 | 0.49 | 0.67 | | | |
| Radiation     | 0.2479               | 0.34                 | 0.0011*              |         |         |         |
| No            | 0.31                 | 0.41                 | 0.61                 |         |         |         |
| Yes           | 0.25                 | 0.38                 | 0.63                 |         |         |         |
| Unknown       | 0.37                 | 0.44                 | 0.61                 |         |         |         |
| Surgery       | <0.0001*             | <0.0001*             | <0.0001*             |         |         |         |
| No            | 0.07                 | 0.09                 | 0.14                 |         |         |         |
| Yes           | 0.30                 | 0.42                 | 0.66                 |         |         |         |
| Unknown       | 0.44                 | 0.36                 | 0.33                 |         |         |         |
| Marital status| <0.0001*             | <0.0001*             | <0.0001*             |         |         |         |
| Single        | 0.39                 | 0.45                 | 0.61                 |         |         |         |
| Married       | 0.30                 | 0.44                 | 0.66                 |         |         |         |
| Other         | 0.15                 | 0.24                 | 0.50                 |         |         |         |
| Unknown       | 0.40                 | 0.40                 | 0.64                 |         |         |         |
| Age           | <0.0001*             | <0.0001*             | <0.0001*             |         |         |         |
| <30           | 0.62                 | 0.66                 | 0.67                 |         |         |         |
| 30–59         | 0.48                 | 0.55                 | 0.72                 |         |         |         |
| 60+           | 0.13                 | 0.24                 | 0.53                 |         |         |         |
| Histology     | <0.0001*             | <0.0001*             | <0.0001*             |         |         |         |
| NOS           | 0.23                 | 0.29                 | 0.45                 |         |         |         |
| Fibromatous   | 0.26                 | 0.41                 | 0.62                 |         |         |         |
| Myxomatous    | NA                   | NA                   | 0.64                 |         |         |         |
| Lipomatous    | 0.34                 | 0.53                 | 0.80                 |         |         |         |
| Myomatous     | 0.26                 | 0.32                 | 0.57                 |         |         |         |
| Synovial      | 0.29                 | 0.38                 | 0.55                 |         |         |         |
| All other types| 0.22                | 0.24                 | 0.50                 |         |         |         |
| Grade         | <0.0001*             | <0.0001*             | <0.0001*             |         |         |         |
| I             | 0.40                 | 0.67                 | 0.89                 |         |         |         |
| II            | 0.39                 | 0.51                 | 0.80                 |         |         |         |
| III           | 0.17                 | 0.30                 | 0.57                 |         |         |         |
| IV            | 0.17                 | 0.26                 | 0.48                 |         |         |         |
| Unknown       | 0.28                 | 0.40                 | 0.14                 |         |         |         |
| Metastasis    | <0.0001*             | <0.0001*             | <0.0001*             |         |         |         |
| No            | 0.30                 | 0.44                 | 0.70                 |         |         |         |
| Yes           | 0.03                 | 0.06                 | 0.14                 |         |         |         |
for local control to various patient- and tumor-related factors, including tumor grade, size, depth relative to the fascia, and surgical margin status, suggesting that each of the factors are important in determining optimal treatment [9, 31–33]. Among the limitations of the current study is the inability to fully assess margin status or to fully evaluate the local recurrence rates, as these are factors that continue to spark controversy regarding their influence on overall survival in ESTS.

The findings of this report corroborate the findings of Alamanda et al., which demonstrated marital status to be an independent predictor of overall survival in ESTS. That study included a study population that was a subset of those used for the current analysis [15]. Their findings demonstrated unmarried patients to have a lower overall survival than married patients (HR: 1.26, CI: 1.05–1.51), which are similar to our results.

A known limitation of the SEER database is the inability to account for the use of chemotherapy in the analysis. Two meta-analyses failed to find an association between adjuvant doxorubicin therapy and overall survival of soft tissue sarcoma [34, 35]. The most recent of these analyses found a statistically significant association between combined adjuvant doxorubicin combined with ifosfamide and improved overall survival. The marginal benefit demonstrated by chemotherapy in these large meta-analyses is far less than the degree of improved survival over time that was shown in the present study. As a result, the authors do not believe that chemotherapy could entirely account for the improved survival seen over the last twenty years.

Cross-sectional population-based studies such as the present study are unable to determine causality but rather elucidate associations between an explanatory variable and survival outcome. While the incidence of extremity soft tissue sarcomas has slightly increased over the study period, the current analysis demonstrates that the 5-year overall survival rates from ESTS have significantly and progressively improved over the course of twenty years, from 28% in the earliest period to 62% in the most recent. These findings are in the setting of seemingly adverse trends of increased age of the patients and more advanced stage of disease over the same time periods. The results are most striking in the older patients, with the seemingly largest improvements being seen in patients older than 30 years old.

In an extensive investigation regarding potential underlying factors that may explain these improvements, multiple independent predictors of survival were again demonstrated. However, none of these factors appear to explain the trend of improved 5-year survival in this cohort. The observation that year of diagnosis remained a significant predictor of survival on multivariate analysis suggests that the improvement in survival of ESTS from 1991 to 2010 may be due to factors that are external to this data. Further work would be beneficial to elucidate the nature of these interesting findings, in order to better understand the underlying explanations for this apparent improvement in overall prognosis, despite worsening rates of traditional prognostic factors of age, tumor size, and the presence of metastasis on presentation.

**Conflict of Interests**

Each author certifies that he or she has no commercial associations (e.g., consultancies, stock ownership, equity interest,
Table 3: Hazard ratios and 95% confidence intervals from multivariate analysis of a 20-year period.

| Characteristic                  | Hazard ratio | 95% CI       | P value |
|---------------------------------|--------------|--------------|---------|
| Year of diagnosis               |              |              |         |
| 2004–2010 Reference group       |              |              |         |
| 1991–1996                       | 3.021        | 2.775, 3.290 | <0.0001* |
| 1997–2003                       | 2.212        | 2.063, 2.371 | <0.0001* |
| Sex                             |              |              |         |
| Male Reference group            |              |              |         |
| Female                          | 0.808        | 0.762, 0.856 | <0.0001* |
| Tumor location                  |              |              |         |
| Lower limb Reference group      |              |              |         |
| Upper limb                      | 0.940        | 0.880, 1.004 | 0.0657  |
| Hispanic ethnicity              |              |              |         |
| Non-Hispanic Reference Group    |              |              |         |
| Hispanic                        | 0.852        | 0.770, 0.942 | 0.0217* |
| Radiation*                      |              |              |         |
| No Reference Group              |              |              |         |
| Yes                             | 0.799        | 0.753, 0.848 | <0.0001* |
| Surgery*                        |              |              |         |
| No Reference Group              |              |              |         |
| Yes                             | 0.436        | 0.399, 0.476 | <0.0001* |
| Marital status*                 |              |              |         |
| Married Reference Group         |              |              |         |
| Other                           | 1.473        | 1.374, 1.578 | <0.0001* |
| Single                          | 1.451        | 1.322, 1.580 | <0.0001* |
| Age                             |              |              |         |
| <30 Reference Group             |              |              |         |
| 30–59                           | 1.698        | 1.462, 1.972 | <0.0001* |
| 60+                             | 3.926        | 3.371, 4.573 | <0.0001* |
| Geographic region               |              |              |         |
| West Reference Group            |              |              |         |
| Midwest                         | 0.937        | 0.850, 1.032 | 0.1849  |
| Northeast                       | 1.103        | 1.008, 1.208 | 0.0323  |
| South                           | 0.998        | 0.898, 1.109 | 0.9740  |
| Histology                       |              |              |         |
| Lipomatous Reference Group      |              |              |         |
| All other types                 | 1.380        | 1.201, 1.586 | <0.0001* |
| Fibromatous                     | 1.119        | 1.019, 1.228 | 0.0187* |
| Myomatous                       | 1.266        | 1.134, 1.413 | <0.0001* |
| Myxomatous                      | 0.982        | 0.667, 1.445 | 0.9267  |
| NOS                             | 1.567        | 1.410, 1.740 | <0.0001* |
| Synovial                        | 1.708        | 1.493, 1.954 | <0.0001* |
| Grade*                          |              |              |         |
| I Reference Group               |              |              |         |
| II                              | 1.557        | 1.352, 1.793 | <0.0001* |
| III                             | 2.581        | 2.260, 2.947 | <0.0001* |
| IV                              | 2.883        | 2.533, 3.282 | <0.0001* |
| Metastasis                      |              |              |         |
| No Reference Group              |              |              |         |
| Yes                             | 3.320        | 3.074, 3.587 | <0.0001* |
| Tumor Size*                     |              |              |         |
| <=5 cm Reference Group          |              |              |         |
| >5 cm                           | 1.743        | 1.620, 1.876 | <0.0001* |
| % Foreign born*                 | 0.992        | 0.988, 0.995 | <0.0001* |
| % < HS education*               | 1.014        | 1.010, 1.019 | <0.0001* |

*Significant on a P < 0.05 level.
NOS: not otherwise specified.

aHRs for variables with “unknown” values are not included in these results.

bHigh school graduation is based upon county-level 2000 census data.
References

[1] E. Koscielniak, M. Morgan, and J. Treuner, “Soft tissue sarcoma in children: prognosis and management,” Pediatric Drugs, vol. 4, no. 1, pp. 21–28, 2002.

[2] M. C. Cheung, Y. Zhuge, R. Yang et al., “Incidence and outcomes of extremity soft-tissue sarcomas in children,” Journal of Surgical Research, vol. 163, no. 2, pp. 282–289, 2010.

[3] A. Ferrari, R. Miceli, M. Casanova et al., “The symptom interval in children and adolescents with soft tissue sarcomas,” Cancer, vol. 116, no. 1, pp. 177–183, 2010.

[4] H. H. Storm, “Survival of adult patients with cancer of soft tissues or bone in Europe. EUROCARE working group,” European Journal of Cancer, vol. 34, no. 14, pp. 2212–2217, 1998.

[5] S. M. Gadgeel, L. C. Harlan, C. A. Zeruto, M. Osswald, and A. G. Schwartz, “Patterns of care in a population-based sample of soft tissue sarcoma patients in the United States,” Cancer, vol. 115, no. 12, pp. 2744–2754, 2009.

[6] M. Koshy, S. E. Rich, and M. M. Mohiuddin, “Improved survival with radiation therapy in high-grade soft tissue sarcomas of the extremities: a SEER analysis,” International Journal of Radiation Oncology Biology Physics, vol. 77, no. 1, pp. 203–209, 2010.

[7] J. K. Horton, J. F. Gleason Jr., H. D. Klepin, S. Isom, D. B. Fried, and A. M. Geiger, “Age-related disparities in the use of radiotherapy for treatment of localized soft tissue sarcoma,” Cancer, vol. 117, no. 17, pp. 4033–4040, 2011.

[8] J. C. Yang, A. E. Chang, A. R. Baker et al., “Randomized prospective study of the benefit of adjuvant radiation therapy in the treatment of soft tissue sarcomas of the extremity,” Journal of Clinical Oncology, vol. 16, no. 1, pp. 197–203, 1998.

[9] P. W. T. Pisters, B. O’Sullivan, and R. G. Maki, “Evidence-based recommendations for local therapy for soft tissue sarcomas,” Journal of Clinical Oncology, vol. 25, no. 8, pp. 1003–1008, 2007.

[10] G. B. Mann, J. J. Lewis, and M. F. Brennan, “Adult soft tissue sarcoma,” Australian and New Zealand Journal of Surgery, vol. 69, no. 5, pp. 336–343, 1999.

[11] A. K. Alderman, H. Myra Kim, S. V. Kotsis, and K. C. Chung, “Upper-extremity sarcomas in the United States: analysis of the surveillance, epidemiology, and end results database, 1973–1998,” Journal of Hand Surgery, vol. 28, no. 3, pp. 511–518, 2003.

[12] L. W. Brien, R. M. Terek, R. J. Geer, G. Cable, M. F. Brennan, and J. H. Healey, “Treatment of soft-tissue sarcomas of the hand,” The Journal of Bone and Joint Surgery—American Volume, vol. 77, no. 4, pp. 564–571, 1995.

[13] M. McPhee, B. E. McGrath, P. Zhang, D. Driscoll, J. Gibbs, and C. Peimer, “Soft tissue sarcoma of the hand,” Journal of Hand Surgery, vol. 24, no. 5, pp. 1001–1007, 1999.

[14] C. P. Karakousis, C. DeYoung, and D. L. Driscoll, “Soft tissue sarcomas of the hand and foot: management and survival,” Annals of Surgical Oncology, vol. 5, no. 3, pp. 238–240, 1998.

[15] M. Manfrini, A. Tiwari, J. Ham, M. Colangelo, and M. Mercuri, “Evolution of surgical treatment for sarcomas of proximal humerus in children: retrospective review at a single institute over 30 years,” Journal of Pediatric Orthopaedics, vol. 31, no. 1, pp. 56–64, 2011.

[16] V. K. Alamanda, Y. Song, and G. E. Holt, “Effect of marital status on treatment and survival of extremity soft tissue sarcoma,” Annals of Oncology, vol. 25, no. 3, pp. 725–729, 2014.

[17] S. R. Martinez, A. S. Robbins, F. J. Meyers, R. J. Bold, V. P. Khatri, and J. E. Goodnight Jr., “Racial and ethnic differences in treatment and survival among adults with primary extremity soft-tissue sarcoma,” Cancer, vol. 112, no. 5, pp. 1162–1168, 2008.

[18] Surveillance-Epidemiology and End Results (SEER) Program and SEER+Stat Database, Incidence—SEER 18 Regs Research Data + Hurricane Katrina Impacted Louisiana Cases, Nov 2012 Sub (1973–2010 varying)—Linked To County Attributes—Total U.S., 1969–2011 Counties, Division of Cancer Control and Population Sciences, National Cancer Institute, Surveillance Research Program, Surveillance Systems Branch, 2013, http://www.seer.cancer.gov/.

[19] Surveillance, Epidemiology, and End Results Program, “Overview of the SEER Program,” January 2015, http://seer.cancer.gov/about/overview.html.

[20] Surveillance, Epidemiology, and End Results Program, “Population Characteristics,” http://seer.cancer.gov/registries/characteristics.html.

[21] National Cancer Institute, Data Flow in NCIs SEER Registries, National Cancer Institute, 2011.

[22] ERS, Rural Classifications, 2014, http://www.ers.usda.gov/topics/rural-economy-population/rural-classifications.aspx.

[23] Surveillance, Epidemiology, and End Results Program. Rural-Urban Continuum Codes, 2014, http://seer.cancer.gov/seerstat/variables/countyattrs/ruralurban.html.

[24] W. B. Al-Refaie, E. B. Habermann, V. Dudeja et al., “Extremity soft tissue sarcoma care in the elderly: insights into the generalizability of NCI cancer trials,” Annals of Surgical Oncology, vol. 17, no. 7, pp. 1732–1738, 2010.

[25] C. DeSantis, J. Ma, L. Bryan, and A. Jemal, “Breast cancer statistics, 2013,” CA: Cancer Journal for Clinicians, vol. 64, no. 1, pp. 52–62, 2014.

[26] D. A. Berry, “Breast cancer screening: controversy of impact,” Breast, vol. 22, supplement 2, pp. S73–S76, 2013.

[27] S. J. Lee, W. J. Boscardin, I. Stijacic-Cenzer, J. Conell-Price, S. O’Brien, and L. C. Walter, “Time lag to benefit after screening for breast and colorectal cancer: meta-analysis of survival data from the United States, Sweden, United Kingdom, and Denmark,” British Medical Journal, vol. 346, Article ID e8441, 2013.

[28] S. Gupta, D. A. Sussman, C. A. Doubeni et al., “Challenges and possible solutions to colorectal cancer screening for the underserved,” Journal of the National Cancer Institute, vol. 106, no. 4, Article ID dju032, 2014.

[29] W. B. Ai-Refaie, E. B. Habermann, E. H. Jensen, T. M. Turtle, P. W. T. Pisters, and B. A. Virmig, “Surgery alone is adequate treatment for early stage soft tissue sarcoma of the extremity,” British Journal of Surgery, vol. 97, no. 5, pp. 707–713, 2010.

[30] P. W. Pisters, L. B. Harrison, D. H. Leung, J. M. Woodruff, E. S. Casper, and M. F. Brennan, “Long-term results of a prospective randomized trial of adjuvant brachytherapy in soft tissue sarcoma,” Journal of Clinical Oncology, vol. 14, no. 3, pp. 859–868, 1996.

[31] T. F. DeLaney, L. Kepka, S. I. Goldberg et al., “Radiation therapy for control of soft-tissue sarcomas resected with positive margins,” Journal of the National Cancer Institute, vol. 85, no. 3, pp. 859–868, 1993.
[33] R. Dagan, L. McGee, C. G. Morris et al., “Is a marginal excision relevant after preoperative radiation therapy for soft tissue sarcoma of the extremity?” *International Journal of Radiation Oncology, Biology and Physics*, vol. 78, no. 3, pp. S1–S86, 2010.

[34] Sarcoma Meta-analysis Collaboration, “Adjuvant chemotherapy for localised resectable soft-tissue sarcoma of adults: meta-analysis of individual data,” *The Lancet*, vol. 350, no. 9092, pp. 1647–1654, 1997.

[35] N. Pervaiz, N. Colterjohn, F. Farrokhyar, R. Tozer, A. Figueredo, and M. Ghert, “A systematic meta-analysis of randomized controlled trials of adjuvant chemotherapy for localized resectable soft-tissue sarcoma,” *Cancer*, vol. 113, no. 3, pp. 573–581, 2008.